Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States

Moosa Tatar, MA; Susana W. Keeshin, MD; Mark Mailliard, MD; Fernando A. Wilson, PhD

Abstract

IMPORTANCE Between 2 and 3.5 million people live with chronic hepatitis C virus (HCV) infection in the US, most of whom (approximately 75%) are not aware of their disease. Despite the availability of effective HCV treatment in the early stages of infection, HCV will result in thousands of deaths in the next decade in the US.

OBJECTIVE To investigate the cost-effectiveness of universal screening for all US adults aged 18 years or older for HCV in the US and of targeted screening of people who inject drugs.

DESIGN, SETTING, AND PARTICIPANTS This simulated economic evaluation used cohort analyses in a Markov model to perform a 10,000-participant Monte Carlo microsimulation trial to evaluate the cost-effectiveness of HCV screening programs, and compared screening programs targeting people who inject drugs with universal screening of US adults age 18 years or older. Data were analyzed in December 2019.

EXPOSURES Cost per quality-adjusted life-year (QALY).

MAIN OUTCOMES AND MEASURES Cost per QALY gained.

RESULTS In a 10,000 Monte Carlo microsimulation trial that compared a baseline of individuals aged 40 years (men and women) and people who inject drugs in the US, screening and treatment for HCV were estimated to increase total costs by $10,457 per person and increase QALYs by 0.23 (approximately 3 months), providing an incremental cost-effectiveness ratio of $45,465 per QALY. Universal HCV screening increased QALY overall by 0.01, with an incremental cost-effectiveness ratio of $291,277 per QALY.

CONCLUSIONS AND RELEVANCE The findings of this study suggest that HCV screening for people who inject drugs may be a cost-effective intervention to combat HCV infection, which could potentially decrease the risk of untreated HCV infection and liver-related mortality.

Introduction

The exact number of individuals in the US who are currently infected with hepatitis C virus (HCV) (presence of HCV RNA) is unknown, but it is estimated to be more than 2 million people and as many as 3.5 million people.1,2 Most individuals with HCV infection (approximately 75%) are not aware of their infection because few symptoms are evident in the early stages of the disease.3,4 However, 70% to 85% of acute HCV infections become a chronic disease.5 Chronic HCV infection is the primary reason for liver cirrhosis and hepatocellular carcinoma and the leading cause of liver transplantation.6
HCV causes nearly 40% of all chronic liver disease and is among the most common indications for liver transplantation in the US. HCV infection accounted for approximately 18,000 deaths in the US in 2016, and HCV infection–related mortality exceeds all other deaths from infectious diseases combined. Most people with HCV in the United States are individuals born between 1946 and 1964 (ie, the Baby Boomers). However, due to the slow progression of hepatitis C disease, the disease may remain undiagnosed for decades. Infection rates among persons who inject drugs (PWID) range from 30% to 90%, depending on frequency and duration of use, and account for approximately 60% of all HCV cases in the US. In 2011, the number of adults and adolescents (US population aged 13 years or older) who had injected drugs in their lifetime was reported to be approximately 6.6 million people. Therefore, while rates of HCV are higher among an older population, the US opioid epidemic has led to an evolving epidemiology of HCV. Sharing needles among PWID is a key risk factor for HCV transmission in US prisons and jails. Inmates in correctional institutions account for up to one-third of all US hepatitis C cases. Compared with a 1% infection rate for the general US population, HCV infection rates are particularly high in correctional institutions and range from 17.4% to 21.3%. One in 10 million people who pass through correctional settings each year have an undiagnosed HCV infection; more than 90% of these individuals are released to the general population. Throughout, these individuals may have little contact with the health care system, and as a result play a prominent role in the spread of HCV in US communities.

HCV treatment can be very effective, especially if HCV is diagnosed in the early stages of the infection. Existing research shows that universal HCV screening in developed countries is effective. Prior studies on the cost-effectiveness of HCV screening in the US examined voluntary screening, specific population groups (eg, individuals born in the Baby Boomer generation, women experiencing pregnancy, volunteers for blood donations, and screening performed in US primary care settings), or older forms of treatment. However, few studies that have assessed the cost-effectiveness of HCV screening in the US account for recent and highly effective treatment regimens for HCV. Furthermore, the cost of new drugs is relatively lower than older drugs; prices for HCV treatments have decreased by approximately half. In the absence of such knowledge, the cost-effectiveness of universal and targeted screening for HCV remains uncertain.

The primary aim of this study was to assess and compare the cost-effectiveness of targeted screening for people who inject drugs with a universal HCV screening program for US adults aged 18 years or older, considering the most effective and recent medical treatments for HCV.

Methods

This study was conducted based on structured reporting of economic evaluations of health interventions according to Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guideline. CHEERS was followed in study assumptions and for reporting the cost-effectiveness analysis of universal HCV screening and targeted screening for PWID. The Common Rule exempts this study from institutional board review because no human participants were involved.

Natural History of HCV

This study was conducted using a decision-analytic Markov model of the natural history and progression of HCV to evaluate the cost-effectiveness of screening for HCV in the US population. The Markov model used in this study, based on the natural history of HCV according to empirically calibrated models, clinical characteristics, and published literature, shows disease progression for a person with HCV infection using a 10-year horizon (Figure 1). The base case at the time of screening and diagnosis was considered 40 years, which is approximately the median age in the US.

Disease progression was described in terms of METAVIR score, a liver biopsy staging system that assesses the severity of liver fibrosis. METAVIR scores assess the degree of scarring or fibrosis.
of the liver, ranging from F0 (no fibrosis) to F4 (cirrhosis). Health states were categorized in 2 main phases of disease progression: fibrosis progression stages F0 to F4, and nonfibrosis progression after stage F4. Health states included healthy (no HCV), no fibrosis (F0), portal fibrosis with no septa (F1), portal fibrosis with few septa (F2), numerous septa without cirrhosis (F3), compensated cirrhosis (F4), decompensated cirrhosis, hepatocellular carcinoma, post-hepatocellular carcinoma, liver transplantation, and post-liver transplantation.40-42 Without treatment, patients in the F0 state might experience spontaneous clearance of the HCV and return to a no HCV state in state F0. Otherwise, patients may progress to the next severity state of the disease (Figure 1). Patients who receive treatment and achieve sustained virologic response will transition to recovered states based on fibrosis severity. Patients with compensated cirrhosis who do not receive treatment will transition to hepatocellular carcinoma or decompensated cirrhosis and may receive liver transplantations. Because natural death could occur while a patient is in any state, likelihood of natural death in the Markov model is based on US life tables.43 Death from the disease can occur in the final nonfibrosis progression states. People may be reinfected at the same rate (1%) as the general population during and after successful treatment and, if reinfeected,44 will begin fibrosis progression from the F0 state. The initial fibrosis state distribution was based on existing literature.45 The fibrosis transition rates (Table 1) vary with age and were based on published literature for HCV in the US, with possible transitions occurring every 12 months.37,39,44

**Treatment**

The treatment regimen included in this analysis was a combination of glecaprevir and pibrentasvir, used to treat chronic HCV genotypes 1, 2, 3, 4, 5, or 6 without cirrhosis or with compensated cirrhosis. The treatment protocol is 3 tablets (100 mg glecaprevir and 40 mg pibrentasvir) taken daily for 8 weeks. The treatment is highly effective, with a success rate of 98%.46 The regimen is not effective for people with advanced cirrhosis (ie, decompensated cirrhosis).
| Variable | Probability | Source |
|----------|-------------|--------|
| **Transition state annual probabilities** | | |
| Fibrosis progression, y | | |
| <40 | 0.04 | Saab et al, 44 2016 |
| 40-49 | 0.04 | Liu et al, 39 2012 |
| 50-59 | 0.09 | Liu et al, 39 2012 |
| 60-69 | 0.155 | Liu et al, 39 2012 |
| 70-79 | 0.2 | Liu et al, 39 2012 |
| ≥80 | 0.285 | Saab et al, 44 2016 |
| Nonfibrosis progression | | |
| Recovered (SVR), no HCV, history of mild or severe fibrosis (compensated cirrhosis) to hepatocellular carcinoma | 0.012 | Saab et al, 44 2016 |
| Compensated cirrhosis to decompensated cirrhosis | 0.04 | Liu et al, 39 2012 |
| Compensated cirrhosis to hepatocellular carcinoma (first year) | 0.02 | Liu et al, 39 2012 |
| Decompensated cirrhosis to hepatocellular carcinoma (first year) | 0.02 | Liu et al, 39 2012 |
| Liver transplantation | | |
| Decompensated cirrhosis to transplantation (first year) | 0.05 | Liu et al, 39 2012 |
| Hepatocellular carcinoma to transplantation (first year) | 0.15 | Liu et al, 39 2012 |
| Liver-related mortality | | |
| Decompensated cirrhosis to liver death | 0.26 | Liu et al, 39 2012 |
| Hepatocellular carcinoma (first year) to liver death | 0.72 | Liu et al, 39 2012 |
| Hepatocellular carcinoma (subsequent year) to liver death | 0.25 | Liu et al, 39 2012 |
| Transplantation to liver death | 0.14 | Liu et al, 39 2012 |
| After transplantation to liver death | 0.05 | Liu et al, 39 2012 |
| Viral reinfection | 0.01 | Saab et al, 44 2016 |
| Spontaneous remission from no fibrosis | 0.012 | Liu et al, 39 2012 |
| Mortality rate total population, y | | |
| <40 | 0.001 | Arias and Xu, 43 2019 |
| 40-49 | 0.002 | Arias and Xu, 43 2019 |
| 50-59 | 0.006 | Arias and Xu, 43 2019 |
| 60-69 | 0.012 | Arias and Xu, 43 2019 |
| 70-79 | 0.026 | Arias and Xu, 43 2019 |
| ≥80 | 0.186 | Arias and Xu, 43 2019 |
| Costs, $ | | |
| Direct medical annual costs by health state | | |
| No HCV | 0 | Assumed |
| Screening | 140 | Carlson, 50 2005 |
| Gileadcaprivir and pibrentasvir regimen (8 wk) | 26 400 | Wholesale acquisition costs, 47 2017 |
| Decompensated cirrhosis treatment | 33 314 | McAdam-Marx et al, 46 2011 |
| Hepatocellular carcinoma treatment | | |
| First year | 52 248 | McAdam-Marx et al, 46 2011 |
| Subsequent years | 52 248 | McAdam-Marx et al, 46 2011 |
| Liver transplantation | | |
| First year | 812 000 | Bentley et al, 37 2003 |
| Subsequent years | 45 481 | McAdam-Marx et al, 46 2011 |
| Variable, value (range) | | |
| Reinfection rate | 0.01 (0.01-0.10) | NA |
| Infection rate for general population | 0.01 (0.01-0.10) | NA |
| Infection rate for people who inject drugs | 0.60 (0.30-0.90) | NA |
| Cost of HCV treatment (drug), $ | 26 400 (2640-52 800) | NA |

Abbreviations: HCV, hepatitis C virus; NA, not applicable; SVR, sustained virologic response.
Cost

Direct medical costs related to HCV included in the study are listed in Table 1. Drug costs in this study were based on wholesale acquisition cost, which is an estimate of the manufacturer's list price and does not include discounts or rebates, and covered the duration of the treatment. Health state medical costs, which are the cost of treatment based on the severity and progress of the disease, were obtained from the published literature on an annual timeframe. Costs considered included visits (inpatient and outpatient), diagnostic and laboratory testing, physician services, emergency department place of service, and pharmacy. The total cost for liver transplantation was obtained from US organ and tissue transplantation cost estimates provided by a prior study. The cost of an HCV screening test was assumed to be $140 based on the existing literature. Finally, the cost of no HCV was assumed to be $0. Costs were inflation-adjusted to 2019 US dollars using the US Consumer Price Index, when necessary.

Statistical Analysis

The primary outcome of this study was quality-adjusted life-years (QALYs) gained, and incremental cost-effectiveness ratios (ICERs) were calculated. Costs were discounted by 3% annually based on recommendations from the US Panel on Cost-effectiveness in Health and Medicine. Life tables from the US Centers for Disease Control and Prevention (CDC) were used for natural mortality rates for the US population. This study was conducted in 2019, and data were analyzed in December 2019. The baseline of analysis was a 40-year old individual in the United States. Cost-effectiveness analysis was conducted using a societal perspective to assess and compare the status quo with screening for HCV under 2 scenarios: annual screening of the total population (universal screening) and targeted screening of PWID. ICERs were calculated by dividing the difference in expected costs of each scenario by the difference in their effectiveness (ie, QALY). The targeted screening scenario is based on a probability of 60% HCV infection in the PWID population vs a probability of 1% under the universal screening scenario. HCV infection rates for PWID depend on frequency and duration of use and range from 30% to 90%.

To determine the expected rates of liver-related mortality, HCV infection, and liver transplantation in the 2 screening scenarios, a 10 000 trial Monte Carlo microsimulation was undertaken. A Monte Carlo microsimulation performs repeated random sampling to get results in a process that cannot easily be estimated and performed. The Monte Carlo microsimulation used in this study estimated the effects of screening if the HCV screening program were scaled to 10 000 people. The microsimulation calculated the results 10 000 times, each time using a different set of random values from the model probability functions to calculate overall totals of liver-related mortality, HCV infection, and liver transplantation for a sample of 10 000 people in a 10-year horizon.

Sensitivity analyses were conducted to measure and evaluate the uncertainty derived from the model assumption. Sensitivity analyses recalculated outcomes under alternative assumptions and used a range of probabilities and values instead of a specific probability and value to determine the association of a variable (ie, reinfection rate, infection rate for both the general population and PWID, cost of HCV treatment) with the outcomes. The TreeAge Pro Healthcare 2019 (TreeAge Software Inc) statistical package was used for all analyses.

Results

Table 2 presents ICERs of costs to QALYs gained for PWID-targeted screening and universal screening compared with the status quo determined by Markov modeling. The PWID screening scenario is based on a probability of 60% HCV infection of this population. In Table 2, the cost per QALY of PWID screening is $2311.50 vs $915.70 for the status quo. Relative to the status quo, screening and treatment of the PWID population is estimated to increase total costs by $10 457 per person on average for a 10 000 Monte Carlo microsimulation trail, resulting in an increase in QALYs.
of 0.23 (approximately 3 months) during their expected lifetime. The ICER in this scenario is estimated to be $44,815 per QALY gained, which is smaller than $50,000 per QALY value. This means that this scenario is cost-effective.

Table 2 also presents the results of universal screening of all US adults in which 1% of the population have HCV infection. The cost per QALY of universal screening is $392.70 vs $14.40 for the status quo. Relative to the status quo, HCV infection for the total US population is estimated to increase total costs by $2845 and shows a very small increase in QALYs of 0.01. The ICER for universal screening is estimated to be $291,277 per QALY gained, which is greater than $50,000 per QALY value. This means this scenario is not cost-effective.

Results from a 10,000 trial Monte Carlo microsimulation analysis showed that PWID screening vs status quo is estimated to reduce liver-related mortality by 88 deaths and new infections by 8754. In addition, the model estimated that the number of liver transplantations decrease by 18 during a 10-year horizon. Results from a 10,000 trial Monte Carlo microsimulation analysis showed that universal screening vs the status quo is estimated to reduce liver-related mortality by 1 death and new infections by 3053 during a 10-year horizon.

Results from the 2-way sensitivity analysis for PWID showed that, based on the assumption that 60% of PWID have HCV infection and the reinfection rate is 1%, the cost of the HCV drug treatment could increase from $26,400 to $29,054 per PWID and ICER would still be less than $50,000 per QALY, meaning HCV screening would still be cost-effective (Figure 2). Additionally, HCV screening for PWID is estimated to be cost-effective over a broad range of HCV infection rates. Given the HCV drug treatment cost of $26,400 per patient, the HCV infection rate could decrease to 40% and ICER
would still be less than $50 000 per QALY; HCV screening would still be cost-effective. Moreover, based on the assumption that 60% of the PWID have HCV infection and that HCV drug treatment costs $26 400 per patient, the reinfection rate could increase to 3.5% and the ICER would still be less than $50 000 per QALY and HCV screening would still be cost-effective.

Universal HCV screening could be cost-effective across a range of HCV infection rates and costs of HCV drug treatment. For example, if the cost of the HCV drug treatment decreased from $26 400 to $13 200 per patient and the infection rate increased to 10%, the ICER would be less than $50 000 per QALY and HCV screening would still be cost-effective. Also, if the infection rate increased to 4% and the cost of the HCV drug treatment decreased to $2 600 per patient, the ICER would be less than $50 000 per QALY and HCV screening would still be cost-effective.

**Figure 3** depicts the associations of independent variations in the probability of HCV infection, the cost of the HCV drug treatment, the probability of a new HCV infection, and the cost of medical treatment by stage of disease. The result of the tornado diagram indicates that the cost of the HCV drug treatment and the probability of HCV infection are the most influential parameters in the model.

**Discussion**

This study examined the cost-effectiveness of universal HCV screening and targeted screening of PWID adult populations for the US using Monte Carlo microsimulation analysis. This analysis used recent data on effectiveness and costs of the pangenotypic regimen of glecaprevir and pibrentasvir as treatment for chronic HCV, which costs approximately half the price of older treatments. Our results showed that HCV screening for PWID is cost-effective with an ICER of $44 815 per QALY. Furthermore, Monte Carlo microsimulation results for a PWID population showed that screening and treatment were associated with prevention of at least 88 HCV-related deaths and reduction in new infections by 8754 cases relative to the status quo. The proposed strategy was associated with avoidance of HCV-related deaths and new infections by 99% and 83%, respectively. In this scenario, screening PWID for HCV was associated in a reduction of the number of liver transplants by 18.

However, universal screening for the total adult US population was not cost-effective in our analysis. Our study findings for PWID-targeted HCV screening were consistent with results of screening of high-risk populations reported in other countries, including the Netherlands, Canada, Japan, and the United Kingdom.28-30,56 Previous studies of HCV screening in the US are mixed. HCV screening is reported to be cost-effective when the prevalence of HCV is high in the total population or in

---

**Figure 3. Associations of Variation in HCV Infection, Cost of Drug Treatment, Probability of New HCV Infection, and Medical Treatment Cost by Stage of Disease**

The dark blue portion of each bar represents the low range of the parameter listed on the y-axis, and the light blue portion of the bar represents the high range of the parameter. When dark blue is on the left and light blue on the right, the ICER increases as the parameter value increases; when light blue is on the left of the baseline, ICER decreases as parameter value increases. EV indicates expected value; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio.
primary care settings. Some studies did not support widespread screening for HCV for average-risk adults. In contrast, other studies suggested that broad screening for the general population can be cost-effective. For example, Eckman et al reported that 1-time universal screening of adults was cost-effective in increasing quality-adjusted QALYs. However, the treatment cost for the advanced stages of the disease was considerably lower, and the drug regimen examined was different and substantially lower in cost than that of the glecaprevir and pibrentasvir regimen examined in our study. A 2018 study from the US Preventive Services Task Force (USPSTF) recommended screening for HCV infection in adults aged 18 to 79 years. However, the USPTF recommendation is based on the effectiveness of screening on improving health outcomes and not on a cost-effectiveness analysis.

Most prior studies that analyzed the cost-effectiveness of HCV screening used data on specific populations or older pharmaceutical treatment protocols than what are currently available. Few studies have assessed the cost-effectiveness of HCV screening in the US considering recently introduced effective treatments of HCV.

In our study, a combination of glecaprevir and pibrentasvir was examined as the drug treatment of early stage HCV. It is a highly effective regimen that is low cost relative to older drug protocols, costing $26 400 for an 8-week treatment period. However, despite the lower cost, screening of all US adults was not found to be cost-effective in our analysis, resulting in an ICER of nearly $300 000 per QALY.

Our study also analyzed the cost-effectiveness of targeted HCV screening for the PWID population. The prevalence of HCV infection among PWID is very high, having been estimated to be between 30% to 90%. Addressing HCV infection among PWID by diagnosing and treating infection in its early stages can prevent many HCV-related complications and deaths in the US and substantially decrease health care expenditures. Our study did not examine how PWID screening may be best accomplished. For example, routine screening of incarcerated populations may be effective. However, ineffective or costly screening programs of PWID will limit the potential cost-effectiveness that we report in our analysis.

Limitations
Our study has limitations. In the Markov model, potential HCV reinfection was assumed to be 1%, which is the probability of infection for the general population. However, HCV reinfection rates are higher among PWID (11%). Furthermore, our model included only direct medical costs. Indirect costs related to HCV treatment may be significant, such as patient mental health status and caregiver costs. We used wholesale acquisition costs, which are frequently used in economic analysis because they are reasonably transparent and consistent. Direct cost estimates were obtained from published sources and may not fully reflect the actual costs of treatment for a particular region or medical system within the US. Finally, our modeling assumes individuals complete the 8-week drug treatment regimen if diagnosed. To the extent that individuals fail to complete the regimen, our analysis may overstate the cost-effectiveness of screening.

Conclusions
Drug injection is a key risk behavior for HCV infection, resulting in an infection rate among PWID of 30% to 90%. If untreated, HCV infection may progress to liver cirrhosis and, ultimately, death. New drug protocols have been developed to successfully treat HCV, and this study examines the cost-effectiveness of targeted screening of PWID and universal screening for the US adult population. Results from our analysis, using an ICER of $50 000 per QALY as a cutoff, suggest that HCV screening that is tailored to PWID is cost-effective in averting premature deaths and liver transplantations associated with HCV disease progression.
Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States

JAMA Network Open. 2020;3(9):e2015756. doi:10.1001/jamanetworkopen.2020.15756 (Reprinted) September 3, 2020 9/12

ARTICLE INFORMATION
Accepted for Publication: June 24, 2020.
Published: September 3, 2020. doi:10.1001/jamanetworkopen.2020.15756
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Tatar M et al.
JAMA Network Open.

Corresponding Author: Moosa Tatar, MA, Department of Population Health Sciences, the University of Utah, 295 Chipeta Way, IN492, Salt Lake City, Utah 84108 (moosa.tatar@utah.edu).

Author Affiliations: Matheson Center for Health Care Studies, the University of Utah, Salt Lake City (Tatar, Wilson); Division of Infectious Disease, the University of Utah School of Medicine, Salt Lake City (Keeshin); University of Nebraska Medical Center College of Medicine, Omaha (Mailliard).

Author Contributions: Mr Tatar and Dr Wilson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Tatar, Keeshin, Mailliard.

Acquisition, analysis, or interpretation of data: Tatar, Keeshin, Wilson.

Drafting of the manuscript: Tatar, Wilson.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Tatar.

Administrative, technical, or material support: Keeshin.

Supervision: Keeshin, Wilson.

Conflict of Interest Disclosures: Dr Mailliard reported receiving grants from Gilead Sciences and AbbVie outside the submitted work. No other disclosures were reported.

REFERENCES
1. Petruzziello A, Mariglano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an update of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824-7840. doi:10.3748/wjg.v22.i34.7824
2. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology. 2006;131(2):478-484. doi:10.1053/j.gastro.2006.06.007
3. Mitchell AE, Colvin HM. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. National Academies Press; 2010.
4. Hagan H, Campbell J, Thiede H, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121(6):710-719. doi:10.1777/003335490612100611
5. US Centers for Disease Control and Prevention. Hepatitis C. Published 2019. Accessed November 6, 2019. https://www.cdc.gov/hepatitis/hcv/index.htm
6. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374. doi:10.1002/hep.22759
7. Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436(7053):973-978. doi:10.1038/nature04083
8. Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017;62(10):2915-2922. doi:10.1007/s10620-017-4684-x
9. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1)(suppl):S58-S68. doi:10.1016/j.jhep.2014.07.012
10. Rosenberg ES, Rosenthal EM, Hall EW, et al. Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1(8):e186371-e186371. doi:10.1001/jamanetworkopen.2018.6371
11. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287-1288. doi:10.1093/cid/ciw111
12. Davis GL, Alter MJ, El-Serag H, Poyntard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):S13-S21. S21.e1-S21.e6. doi:10.1053/j.gastro.2009.09.067
13. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-1858. doi:10.1086/588297
14. US Centers for Disease Control and Prevention. Surveillance Data for Viral Hepatitis. Published 2016. Accessed June 4, 2020. https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm

15. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis. 2006;42(5):673-676. doi:10.1086/499960

16. Klevens RM, Liu S, Roberts H, Jiles RB, Holmberg SD. Estimating acute viral hepatitis infections from nationally reported cases. Am J Public Health. 2014;104(3):482-487. doi:10.2105/AJPH.2013.301601

17. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-278. doi:10.7326/0003-4819-156-4-201202210-00004

18. Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9(5):e97596. doi:10.1371/journal.pone.0097596

19. Spaulding AC, Weinbaum CM, Lau DT-Y, et al. A framework for management of hepatitis C in prisons. Ann Intern Med. 2006;144(10):762-769. doi:10.7326/0003-4819-144-10-200605160-00010

20. Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep. 2014;129(2):187-195. doi:10.1177/00333549142900213

21. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353-1363. doi:10.1002/hep.27978

22. Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA. 2012;307(12):1259-1260. doi:10.1001/jama.2012.374

23. Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. N Engl J Med. 2014;370(20):1871-1874. doi:10.1056/NEJMpt1311941

24. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94(7):1218-1223. doi:10.2105/AJPH.94.7.1218

25. Rich JD, Chandler R, Williams BA, et al. How health care reform can transform the health of criminal justice-involved individuals. Health Aff (Millwood). 2014;33(3):462-467. doi:10.1377/hlthaff.2013.1133

26. Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. June 16, 2016. Accessed July 20, 2020. http://www.theguardian.com/us-news/2016/jun/16/us-prisons-jail-private-healthcare-companies-profit

27. Alomar MJ, Al Zaabi AN, Hassan NA, Strauch CC, Al Zaabi ME, Shahwan MJ. Safety and economic evaluation of patients treated for hepatitis with antiviral daclatasvir and sofosbuvir combined vs ledipasvir/sofosbuvir 90mg/400mg in a medical institution in the UAE. J of Pharm Sci and Res. 2018;10(3):28-40. doi:10.17496/jpsr.2018.3.10.28-40

28. Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for hepatitis C in injecting drug users: a cost utility analysis. J Public Health (Oxf). 2004;26(1):61-71. doi:10.1093/pubmed/fdh109

29. Wong WWL, Tu H-A, Feld JJ, Wong T, Kahin M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015;187(3):E110-E121. doi:10.1503/cmaj.140711

30. Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med. 2008;215(1):33-42. doi:10.1620/txm.215.33

31. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013;56(10):1382-1393. doi:10.1093/cid/cit069

32. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156(4):263-270. doi:10.7326/0003-4819-156-4-201202210-00037

33. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol. 2005;192(4):1153-1161. doi:10.1016/j.ajog.2004.10.600

34. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2001;111(6):614-621. doi:10.1016/S0002-9343(01)00951-2

35. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004;86(1):28-40. doi:10.1111/j.1872-8296.2004.00379.x
36. Husereau D, Drummond M, Petrou S, et al; CHEERS Task Force. Consolidated health economic evaluation reporting standards (CHEERS) statement. *Int J Technol Assess Health Care*. 2013;29(2):117-122. doi:10.1017/S0266462313000160

37. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228-237. doi:10.1001/jama.290.2.228

38. Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. *PLoS One*. 2011;6(12):e26783. doi:10.1371/journal.pone.0026783

39. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. *Ann Intern Med*. 2012;156(4):279-290. doi:10.7326/0003-4819-156-4-201202210-00005

40. Liao R, Fu Y-P, Wang T, et al. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. *Oncotarget*. 2017;8(1):1774-1787. doi:10.18632/oncotarget.12152

41. Poynard T, Vergniol J, Ngo Y, et al; FibroFrance Study Group; Epic3 Study Group; Bordeaux HCV Study Group. Staging chronic hepatitis C in seven categories using fibrosis biomarker and transient elastography. *J Hepatol*. 2014;60(4):706-714. doi:10.1016/j.jhep.2013.11.016

42. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. *J Hepatol*. 2003;38(2):223-229. doi:10.1016/S0168-8278(02)00357-4

43. Arias E, Xu J. United States life tables, 2017. *National Vital Statistics Reports*, 68(7). US Department of Health and Human Services; 2019. Accessed July 23, 2020. https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07-508.pdf

44. Saab S, Parisé H, Virabhak S, et al. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. *J Med Econ*. 2016;19(8):795-805. doi:10.1080/13696998.2016.1176030

45. Siddiqui FA, Ehrinpreis MN, Janisse J, Dhar R, May E, Mutchnick MG. Demographics of a large cohort of urban chronic hepatitis C patients. *Hepatol Int*. 2008;2(3):376-381. doi:10.1007/s12072-008-9086-x

46. Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. *Hepatol Int*. 2018;12(3):214-222. doi:10.1007/s12072-018-9873-y

47. Elliott W, Chan J. Glecaprevir and Pibrentasvir Tablets (Mavyret). *Intern Med Alert*. 2017;39(18). https://www.reliasmedia.com/articles/141417-glecaprevir-and-pibrentasvir-tablets-mavyret

48. McMAdam-Marx C, McGarry LI, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. *J Manag Care Pharm*. 2011;17(7):531-546. doi:10.8553/jmcp.2011.17.7.531

49. Bentley TS, Phillips JS, Hanson SG. 2017 US organ and tissue transplant cost estimates and discussion. Milliman Research Report; 2017. Accessed July 20, 2020. https://milliman-cdn.azureedge.net/-/media/milliman/importedfiles/uploadedfiles/insight/2017/2017-transplant-report.ashx

50. Carlson B. HCV testing cost-effective alternative to treating advanced disease. *Biotechnol Healthc*. 2005;2(5):12-14.

51. US Department of Labor Bureau of Labor Statistics. Consumer Price Index. Published 2019. Accessed November 13, 2019. https://data.bls.gov/cgi-bin/cpicalc.pl?cost1=104.00&year1=200501&year2=201910

52. Siegel JE, Weinstein MC, Russell LB, Gold MR; Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. *JAMA*. 1996;276(16):1339-1341. doi:10.1001/jama.1996.03540160061034

53. Weinstein MC, Russell LB, Gold MR, Siegel JE. *Cost-Effectiveness in Health and Medicine*. Oxford University Press; 1996.

54. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. *Hepatology*. 2019;69(3):1020-1031. doi:10.1002/hep.30297

55. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? *Arch Intern Med*. 2003;163(14):1637-1641. doi:10.1001/archinte.163.14.1637

56. Helser CW, Borkent-Raven BA, de Wit NJ, et al. Cost-effectiveness of targeted screening for hepatitis C in the Netherlands. *Epidemiol Infect*. 2012;140(1):58-69. doi:10.1017/S0950268811003112

57. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. *Clin Infect Dis*. 2012;54(9):1259-1271. doi:10.1093/cid/cis011
58. Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens. Clin Gastroenterol Hepatol. 2019;17(5):930-939.e9. doi:10.1016/j.cgh.2018.08.080

59. Des Jarlais DC, Arasteh K, Feeleyer J, et al. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: protective effects of non-injecting drug use. Drug Alcohol Depend. 2018;192:74-79. doi:10.1016/j.drugalcdep.2018.07.034

60. Midgard H, Bjoro B, Maeland A, et al. Hepatitis C reinfection after sustained virological response. J Hepatol. 2016;64(5):1020-1026. doi:10.1016/j.jhep.2016.01.001

61. Levy J, Rosenberg M, Vanness D. A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses. Value Health. 2018;21(6):677-684. doi:10.1016/j.jval.2017.06.013